Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1002 +/- CS1003 in Advanced Solid Tumors
NCT03523819Phase 1Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Apr 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CS1002 in solid tumor (2 arms), sponsored by CStone Pharmaceuticals. Primary endpoint: Number of participants with adverse events. Started Apr 2018; status: completed.
02
Drugs
CS1002
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03523819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03523819.